Anti-IL-12 antibodies

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387100, C530S387300, C530S387900

Reexamination Certificate

active

08080247

ABSTRACT:
An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

REFERENCES:
patent: 5457038 (1995-10-01), Trinchieri et al.
patent: 5547852 (1996-08-01), Seller et al.
patent: 5648467 (1997-07-01), Trinchieri et al.
patent: 5780597 (1998-07-01), Gately et al.
patent: 5811523 (1998-09-01), Trinchieri et al.
patent: 5891680 (1999-04-01), Lieschke et al.
patent: 6086876 (2000-07-01), Karp et al.
patent: 6225117 (2001-05-01), Gately et al.
patent: 6300478 (2001-10-01), Trinchieri et al.
patent: 6338848 (2002-01-01), Leonard et al.
patent: 6495667 (2002-12-01), Bazan
patent: 6914128 (2005-07-01), Salfeld et al.
patent: 790255 (1997-08-01), None
patent: 433827 (1998-03-01), None
patent: 804581 (2001-09-01), None
patent: WO 90/05147 (1990-05-01), None
patent: WO 92/05256 (1992-04-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 97/15327 (1997-05-01), None
patent: WO 97/15327 (1997-05-01), None
patent: WO 99/37682 (1999-07-01), None
patent: WO 00/56772 (2000-09-01), None
patent: WO 01/19373 (2001-03-01), None
patent: WO 02/12500 (2002-02-01), None
patent: WO 02/097048 (2002-12-01), None
Gubler, et al., “Coexpression of Two Distinct Genes is Required to Generate Secreted Bioactive cytotoxic Lymphocyte Maturation Factor,” Proceedings of the National Academy of Science USA vol. 88, 4143-4147 (1991).
Gubler, et al., “Clonic and Expression of Cytotoxic Lymphocyte Maturation Factor a Heterodimeric Lymphokine that Potentiates NR LAK NA D T-Cell Responses,” Abstracts of the Journal of Cellular Biochemistry Supplement 15F 70 (1991).
Stern, et al., “Purification to Homogeneity and Partial Characterization of Cytotoxic Lymphocyte Maturation Factor From Human B-Lymphoblastoid Cells,” Proceedings of the National Academy of Science, 87: 6808-6812 (1990).
Gately, et al., “Regulation of Human Lymphocyte Proliferation by a Heterodimeric Cytokine IL-12,” The Journal of Immunology, 147: 874-882 (1991).
Chizzonite, et al., “IL-12 Monoclonal Antibodies Specific for the 40-KdA Subunit Block Receptor Binding and Biologic Activity on Activated Human Lymphoblasts,” 147: 1548-1556 (1991).
Chan, et al., “Introduction of Interferon Production by Natural Killer Cell Stimulatory Factor Characterization of the Responder Cells and Cynergy with Other Inducers,” Journal of Experimental Medicine, 173: 869-879 (1991).
D'Andrea, et al., “Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cell,” Journal of Experimental Medicine, 176: 1387-1398 (1992).
Neurath, et al., “Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in Mice,” The Journal of Experimental Medicine, 182: 1281-1290 (1995).
Carter, et al., “Production and characterization of Monoclonal Antibodies to Human Interleukin-12,” Hybridoma, 16: 363-369 (1997).
Valiante, et al., “Role of the Production of Natural Killer Cell Stimulatory Factor NKSF/IL-12) in the Ability of B Cell Lines to Stimulate T and NK Cell Proliferation,” Cellular Immunology, 145: 187-198 (1992).
Duchmann, et al., “Tolerance Towards Resident Intestinal Flora in Mice is Abrogated in Experimental Colitis and Restores by Treatment with Interleukin-1 or Antibodies to Interleukin-12,” European Journal of Immunology, 26: 394-398 (1996).
Kobayashi, et al., “Identification and Purification of Natural Killer Cell Stimulatory Factor (NKFS) a cytokine iwht Multiple Biologic Effects on Human Lymphocytes,” Journal of Experimental Medicine, 170: 827-845 (1989).
Trembleau, et al., “The Role of IL-12 in the Induction of Organ-Specific Autoimmune Diseases,” Immunology Today, 16(8): 383-386 (1995).
Ywalkar, et al., “Expression of interleukin-12 is increased in psoriatic skin,” Journal of Investigative Dermatology, 111(6): 1053-1057 (1998).
Swiss-Prot Accession No. P29459, Mar. 3, 2009.
Kauffman, et al., The Journal of Investigative Dermatology, 123(6): 1037-1044 (2004).
Li, et al., “Anti-IL-12 p40 mAb prevents diabetes onset by inducing active immune suppression,” FASEB Journal, 17(7): C270 (2003).
Mannon, et al., “Anti-Interleukin-12 Treats Active Crohn's Disease,” Gastroenterology, 26(4): A22-A23 (2004).
Mosby, et al., Abstracts 1230-1260, Journal of Allergy and Clinical Immunology, 99(1): S301-S400 (1997).
Supplemental EP Search Report dated Mar. 20, 2009.
Amit, et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution,” Science, 233(4765): 747-753 (1986).
Eck, et al., “Chapter 5—Scope of Gene Therapy,” Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill (1996).
Lonberg, et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature, 368: 856-859 (1994).
Panka, et al., “Variable Region Framework Differences Result in Decreased or Increased Affinity ofVariant Anti-Digoxin Antibodies,” Proceedings of the National Academy of Sciences of he United States of America, 85(9): 3080-3084 (1988).
PCT International Search Report dated Jun. 1, 2007.
Supplementary European Search Report dated Mar. 20, 2009.
Swiss-Prot Accession No. P29460, Apr. 1, 1993.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Anti-IL-12 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-IL-12 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-12 antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4305387

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.